Silver Book

Silver Book Fact

Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient– a glaucoma treatment that delays the disease progression could significantly reduce its economic burden.

Lee P, Walt J, Doyle J, Kotak S, et al. A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124(1): 12-9. http://archopht.ama-assn.org/cgi/content/abstract/124/1/12

Reference

Title
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma
Publication
Archives of Ophthalmology
Publication Date
2006
Authors
Lee P, Walt J, Doyle J, Kotak S, et al.
Volume & Issue
Volume 124, Issue 1
Pages
12-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • A study on the impact of diet on age-related macular degeneration (AMD) found that those who took the highest amounts of carotenoids, such as lutein and zeaxanthin, had a 43%…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…